TYPE 1 DIABETESMANAGEMENTCLINICAL TRIAL
Evaluating a novel adjunct therapy to improve glycemic control and reduce insulin requirements in adults with Type 1 Diabetes in New York City.
Study Overview
Type 1 Diabetes requires lifelong insulin therapy, yet many patients struggle to achieve optimal glycemic control despite their best efforts. This clinical research study evaluates the safety and efficacy of a novel adjunct therapy designed to work alongside insulin, potentially improving HbA1c levels, reducing glycemic variability, and decreasing the burden of diabetes management.
Duration
36-52 Weeks
Target Group
Adults 18-65
Participants must meet the following criteria to be eligible for the study:
- Adults 18-65 years of age
- Confirmed diagnosis of Type 1 Diabetes for at least 12 months
- Current use of insulin therapy (multiple daily injections or pump)
- HbA1c between 7.5% and 11.0% at screening
- Stable insulin regimen for at least 3 months prior to enrollment
- Willing to perform regular blood glucose monitoring
- No severe hypoglycemia episodes in the past 3 months
- Provide written informed consent
Apply Now
See if you qualify for this study
Participant Safety is Our Priority
Ethical Oversight
All studies are reviewed and approved by an Institutional Review Board (IRB) to ensure participant safety and rights.
Informed Consent
We provide clear, detailed information about the study before you decide to participate, and you can withdraw at any time.
Expert Monitoring
Participants receive regular health check-ups and are closely monitored by our team of medical professionals.